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Abstract 
Manipulation of the ubiquitin–proteasome system to achieve targeted degradation of 
proteins within cells using chemical tools and drugs has the potential to transform 
pharmacological and therapeutic approaches in cancer and other diseases. An 
increased understanding of the molecular mechanism of thalidomide and its 
analogues following their clinical use has unlocked small molecule modulation of the 
substrate specificity of the E3 ligase cereblon, which in turn has resulted in new 
immunomodulatory drugs (IMiDs) advancing in the clinic.. The degradation of 
multiple context-specific proteins by these pleiotropic small molecules provides a 
means to uncover new cell biology as well as generate future drug molecules against 
currently undruggable targets. In parallel, the development of larger bifunctional 
molecules that bring together highly specific protein targets in complexes with 
cereblon, von Hippel-Lindau or other E3 ligases to promote ubiquitin-dependent 
degradation has progressed to generate selective chemical compounds with potent 
effects in cells and in vivo models, providing valuable tools for biological target 
validation and with future potential for therapeutic use. In this review, we survey 
recent breakthroughs achieved in these two complementary methods and the 
discovery of new modes of direct and indirect engagement of target proteins with the 
proteasome. We discuss the experimental characterisation that validates the use of 
molecules that promote protein degradation as chemical tools, the preclinical and 
clinical examples disclosed to date, and the future prospects for this exciting area of 
chemical biology. 
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1. Introduction 
The process by which proteins are systematically degraded in a timely manner 
represents a fundamental mechanism for maintaining protein and cellular 
homeostasis. Protein homeostasis is mainly regulated by the ubiquitin–proteasome 
pathway, which was initially discovered by studying the degradation of denatured 
globin in reticulocyte lysates by the seminal work of Ciechanover, Hershko and Rose 
(Ciechanover et al., 1978; Hershko et al., 1979). Their work showed that proteins 
were targeted for degradation in an ATP-dependent manner by covalent conjugation 
of multiple molecules of an ATP-dependent proteolytic factor APF-1, later identified 
as ubiquitin. Subsequent work showed that ubiquitin mediated protein degradation 
occurs in a stepwise manner through an enzymatic cascade starting with activation 
of ubiquitin by the E1 ubiquitin ligase enzymes (UBEs), ubiquitin-like modifier-
activating enzymes (UBAs) 1 and 6. Activated ubiquitin is then transferred to a 
ubiquitin-conjugating enzyme E2, of which there are approximately 30 examples. 
Subsequently the members of the E3 ligase family (consisting of approximately 600 
enzymes) transfer ubiquitin to the target protein substrate (Bett 2016).  
Polyubiquitination occurs via the creation of isopeptide bonds between the C-
terminal glycine of ubiquitin and the N-terminal methionine or one of several lysine 
residues in the substrate ubiquitin. Attachment of multiple ubiquitin molecules 
through conjugation to lysine-48 residues is associated with protein degradation via 
the proteasome. On the other hand, polyubiquitination via lysine-63 is associated 
with creating scaffolds for cell signalling and other critical biological processes 
(Komander & Rape, 2012). Ubiquitination is reversed by approximately 100 
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deubiquitinase enzymes (DUBs) that are proteases consisting of 5 sub-families:  
ubiquitin specific proteases (USP), ubiquitin carboxyl-terminal hydrolases (UCH); 
ovarian tumour-like (OTUs); Machado-Joseph disease (MJD) protein domain 
proteases and the JAMM (JAB1/MPN/MOV34) metalloprotease family (McClurg & 
Robson, 2015). 
The E3 ligases consist of 4 different classes of enzymes (Nakayama & Nakayama 
2006). These include the really interesting new gene (RING) domains, that recognise 
target proteins and mediate transfer of ubiquitin from E2; the homologous to the E6-
AP carboxyl terminus (HECT) domains, which transfer ubiquitin to their own cysteine 
residues and then onto the target substrate protein; the u/box E3 ligases that 
function like RING E3 ligases, having a RING-like domain but lack the cysteine and 
histidine zinc co-ordination sites; finally, the recently described RING-in-between-
RING (RBR) family which behave as a hybrid between RING and HECT enzymes. 
The largest family of E3 ligases are the cullin-RING ligases (CRLs), which play a role 
in many diverse cellular processes (Sang et al., 2015). Most CRL E3 ligases are 
assembled in a modular form (Sarikas et al., 2011), where the cullin (CUL) protein 
acts as a molecular scaffold that assembles the multi-subunit CRL complexes. The 
functional complexes consist of four subunits – the cullin protein which engages a 
receptor protein for substrate recognition, an adaptor protein, and a RING finger E3 
ligase that binds to a ubiquitin charged E2 that catalyses the transfer of ubiquitin to 
specific substrates. A major component of this review concerns the cullin-RING 
ligase 4 (CRL4) family, and Figure 1 shows the key components for this complex. 
Cereblon (CRBN) is the substrate receptor for this CRL4 complex, with DNA damage 
binding protein 1 (DDB1) serving as the adapter protein and cullin 4 (CUL4) as the 
scaffold. Substrate receptors interacting with DDB1 are also known as DDB1 and 
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CUL4 associated factors (DCAFs) (Angers et al., 2006). There are a large number of 
DCAFs, including CRBN, that are involved in the targeting of a wide range of 
substrates for ubiquitination, resulting in the regulation of a broad range of essential 
cellular processes including DNA repair, DNA replication, and chromatin remodelling 
(Lee & Zhou, 2007). Roc1 (also called Rbx1) is the RING finger E3 ligase that is part 
of the CRL4CRBN complex. 
Given the critical role of the ubiquitin–proteasome system in cellular physiology and  
its dysregulation in a number of diseases including cancer, neurodegenerative 
diseases, infections, metabolic disorders and inflammation, there is a great deal of 
recent endeavour to target components of this system for drug discovery and 
development. Indeed it has been suggested that the current efforts mirror the 
enthusiasm for targeting the kinases in the late 1990s and 2000s (Cohen & Alessi, 
2013). The aim of this review is to critically evaluate the current work and convey the 
excitement for using chemical approaches for targeting protein degradation through 
modulation of the ubiquitin–proteasome pathway. A key early exemplar of success in 
this area was the development of proteasome inhibitors such as bortezimib and 
carfilzomib (Mina et al., 2016). More recently, targeting of neddylation, which is 
related to the ubiquitin–proteasome pathway, has also shown promising results 
(Duncan et al., 2012). There is also a great deal of effort to target the DUBs 
(McClurg & Robson, 2015). 
In this review, we will focus on two complementary approaches to achieve targeted 
protein degradation (Figure 2A). Firstly, we consider how small molecules can be 
used to directly modulate the CRL4CRBN complex to change its specificities for 
substrate binding and thus redirect the spectrum of target degradation. This has 
already led to small molecule drugs effective in haematological cancers (Zeldis et al., 
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2011). Second, we survey the substantial recent data and examples demonstrating 
how CRBN and other E3 ligases may be hijacked by bifunctional molecules 
designed to deliver specific target proteins to the complex for ubiquitination and 
degradation (Toure & Crews, 2016; Deshaies, 2015; Lei et al., 2016; Lu et al., 2015; 
Winter et al., 2015). This approach has already delivered chemical tools that allow 
target depletion in cells or in vivo to be studied using pharmacological agents as well 
as RNA interference or other genetic methods. Furthermore, we discuss how some 
of these approaches may enable the drugging of hitherto difficult to drug proteins.   
 
2. Direct modulation of cereblon E3 ligase substrate specificity by small 
molecules 
In the early 1960s, thalidomide was infamously withdrawn from the market after 
reports of severe birth deformities in infants born to women who took the anti-
morning sickness drug during pregnancy. Since then thalidomide has been 
demonstrated to be effective in treating a complication of leprosy and also multiple 
myeloma (MM), owing to its anti-angiogenic, immunomodulatory and anti-
inflammatory properties (Marriott et al., 1999; Raje et al., 1999; Stephens et al., 
2000; Bartlett et al., 2004). However, thalidomide’s molecular target remained 
unknown until 2010 when Hiroshi Handa’s laboratory in Tokyo discovered through a 
series of affinity purification assays that thalidomide directly binds to cereblon 
(CRBN) and inhibits its ubiquitination (Ito et al., 2010). Notably, Ito and colleagues 
showed that the phthalimide portion of the thalidomide structure did not bind to 
CRBN and that CRBN is the protein target of thalidomide responsible for 
thalidomide-mediated teratogenesis in zebrafish (Ito et al., 2010).  
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The revival of thalidomide’s clinical utility has since led to the development of more 
potent and less toxic analogues known as immunomodulatory derivatives (IMiDs), 
such as lenalidomide and pomalidomide (Figure 2B). CRBN was also identified as 
the target of lenalidomide and pomalidomide, and is responsible for the 
immunomodulatory and antiproliferative activities of these agents in MM (Lopez-
Girona et al., 2012). It was hypothesised that IMiDs alter the abundance, localisation 
and activity of CRLCRBN E3 ligase substrates (Zhu et al., 2011; Lopez-Girona et al., 
2012) (Figure 3A, B). Three studies in 2014 by the Ebert, Kaelin and Chopra groups 
(Gandhi et al., 2014; Krönke et al., 2014; Lu et al., 2014) showed that these changes 
arise from the ability of IMiDs to alter cereblon’s E3 ligase substrate preference, 
resulting in the ubiquitination and degradation of the transcription factors Ikaros 
(IKZF1) and Aiolos (IKZF3). The data from these and subsequent studies also 
demonstrated that Ikaros and Aiolos degradation was dependent on the presence of 
IMiDs and therefore represents drug-induced neomorphic activity, with Ikaros and 
Aiolos identified as neosubstrates of the CRBN E3 ligase complex (Licht et al., 
2014). It was subsequently shown that in MM, proteasomal degradation of Ikaros 
and Aiolos resulted in the downregulation of c-MYC followed by a decrease in 
interferon regulatory factor 4 (IRF4) expression, and that this was associated with 
growth inhibition and apoptosis. These results suggested a functional link between 
Ikaros and Aiolos, and the pathological deregulation of c-MYC and IRF4 in MM, 
which had hitherto not been described (Bjorklund et al., 2015; Hagner et al., 2015). 
Furthermore, the degradation of Aiolos and Ikaros in T cells (Gandhi et al., 2014) 
explained, at least in part, the activation of the immune system seen in patients 
receiving IMiD compounds (Gandhi et al., 2013). Both Aiolos and Ikaros were shown 
to be repressors of T cell function and their degradation results in interleukin 2 (IL-2) 
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production and T cell activation. Of note, lenalidomide and known existing 
thalidomide analogues do not impact Aiolos and c-MYC in epithelial tumours 
suggesting that Aiolos and c-MYC are regulated through different mechanisms in this 
context compared to B-cell malignancies.  
Recently, the enzyme casein kinase 1α (CK1α) was discovered as a target of 
ubiquitin-mediated degradation in the presence of lenalidomide. Treatment with 
lenalidomide resulted in almost complete loss of CK1α in primary human stem cells 
derived from patients with myelodysplastic syndrome (del (5q) MDS) (Krönke et al., 
2015). The gene that encodes CK1α, CSNK1A1, is on the long arm of chromosome 
5, and is haploinsufficient in del (5q) MDS. CK1α regulates the activity of multiple 
proteins; for example, it negatively regulates TP53, a tumour-suppressor protein 
(Schneider et al., 2014) and therefore degradation of CK1α by lenalidomide restores 
TP53 and leads to clonal extinction of the del (5q) clone. This demonstrates that 
thalidomide analogues that change E3 ligase substrate specificity have the ability to 
unearth novel biology and, furthermore, to modulate a hitherto difficult to drug 
pathway. In this study, thalidomide, pomalidomide and CC-122, a novel CRBN-
binding molecule (Figure 2B) did not degrade CK1α, highlighting that even though 
these compounds have similar chemical structures, with a shared glutarimide ring, 
they have unique as well as common substrate-modifying specificities. 
The difference in CRBN-E3 ligase substrate specificity was recently explained by 
elucidation of the crystal structures of the DDB1–CRBN complex bound to 
thalidomide, lenalidomide and pomalidomide, reported by both the Celgene and 
Thoma groups (Chamberlain et al., 2014; Fischer et al., 2014). These structures 
establish that CRBN is a substrate receptor within the CRL4CRBN complex that 
enantioselectively binds IMiD compounds. The glutarimide ring of thalidomide and its 
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analogues binds into a hydrophobic tritrytophan pocket, termed the Thalidomide-
Binding Domain (TBD), which is evolutionarily conserved from Archea to higher 
mammals (Bhogaraju and Dikic, 2014; Krönke et al., 2015). The phthalimide ring is 
exposed on the surface of the CRBN protein and alters the surface of the E3 ligase 
substrate receptor to enable interaction with new substrates. More recently, the 
Thoma group extended the work on CK1α by elucidating a highly informative 2.45 Å 
co-crystal structure of DDB1-CRBN bound to lenalidomide and CK1α (Petzold et al., 
2016). In this structure, CRBN and lenalidomide jointly provide the binding interface 
for a CK1α β-hairpin loop located in the kinase N-lobe. Interestingly, the structure 
reveals that CK1α binding to CRL4CRBN is strictly dependent on the presence of an 
IMiD (Petzold et al., 2016). Moreover, the presence of Gly40 in the β-hairpin loop is 
important for mediating the degradation of target substrates, implying that this 
residue may form part of the protein degradation motif (degron) recognised by the 
IMiD-CRBN complex. Furthermore, the binding of Ikaros to CRBN similarly requires 
the presence of an IMiD compound, and both protein substrates, Ikaros and CK1α, 
adopt a related binding mode. These important high-affinity protein-protein 
interactions, which are specifically induced by small molecules, will provide 
opportunities for future drug discovery, particularly for targeted protein degradation.  
It is expected that the binding of IMiDs to CRBN will displace endogenous 
substrates, of which little is known, and promote the recruitment of neosubstrates 
(Figure 3A, B). Recently, the homeobox gene MEIS2, was identified as an 
endogenous substrate of CRBN whereby MEIS2 ubiquitination is inhibited by the 
IMiDs, resulting in increased protein levels. These data indicate that IMiDs modulate 
ubiquitination; in some instances, creating a neomorph for substrate degradation, as 
for Aiolos and Ikaros, and in others, competing out endogenous substrates, such as 
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MEIS2, thereby leading to a decrease in their degradation (Fischer et al., 2014). 
More recently, glutamine synthetase (GS) has also been shown to be an 
endogenous substrate of CRL4CRBN (Nguyen et al., 2016). GS recognition by CRBN 
leads to its polyubiquitination by CRL4CRBN in response to high glutamine levels. 
Contrary to the case of MEIS2, IMiDs enhance GS binding to CRBN. Furthermore, 
two lysine resides (K11 and K14) in the N-terminus of GS are acetylated by 
p300/CBP in response to high glutamine concentrations. These acetylation marks 
serve as a degron to allow CRBN binding and CRL4CRBN-mediated ubiquitination. 
These data suggest that, so far, there does not appear to be an identifiable, 
universally conserved degron motif and that CRL4CRBN-mediated degradation of 
substrates is likely to be dependent on both the cellular context and metabolic state 
of the cell.  
CC-122 and CC-885 are the most recently developed IMiDs (Figure 2B). CC-122 is a 
pleiotropic pathway modifier that also binds CRBN and promotes degradation of 
Aiolos and Ikaros in diffuse large B-cell lymphoma (DLBCL) T-cells in vitro, in vivo, 
and in patients, resulting in both cell autonomous as well as immune-stimulatory 
effects. In DLBCL cell lines, both CC-122-induced degradation and short hairpin 
RNA-mediated knockdown of Aiolos and Ikaros correlates with increased 
transcription of interferon (IFN)-stimulated genes; this is independent of IFN-α, -β, 
and -γ production and/or secretion, and results in apoptosis in both activated B-cell 
(ABC) and germinal centre B-cell DLBCL cell lines (Hagner et al., 2015). This drug is 
now entering Phase II/III studies for poor risk lymphoma patients. 
CC-885 is the first IMiD to demonstrate potent anti-tumour activity in both 
haematological and epithelial cancers (Matyskiela et al., 2016). In addition to 
inducing CRBN-mediated degradation of Ikaros as seen with other thalidomide 
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analogues, CC-885 promotes the degradation of the translation termination factor 
GSPT1, resulting in cytotoxicity. Lenalidomide and pomalidomide do not degrade 
GSPT1, possibly due to their lack of the extended urea moiety of CC-885 that 
enables additional interactions with CRBN and GSPT1. Intriguingly, structural 
studies of CRBN-DDB1 with CC-885 and GSPT1 revealed that CC-885 creates a 
hotspot on the CRBN surface for direct interaction with GSPT1 and this interaction is 
not determined by a peptide sequence but rather by the geometric arrangement of 
three hydrogen bond acceptors on the GSPT1 backbone and the precise position of 
its glycine residue.  
It is clear that the ability of IMiDs to direct CRL4CRBN to degrade several different 
proteins opens up the potential to discover and target hitherto undruggable proteins 
and pathways. This approach will be even more powerful if we are able to predict 
and select which proteins are degraded. One avenue is to use sequence and 
structural homologies in putative CRL4CRBN degrons to define potential substrate 
proteins and to design small molecule CRL4CRBN binders that can selectively direct 
the degradation of these proteins. This rational design approach complements the 
empirical phenotypic screening employed to discover the existing IMiDs. Currently, 
defined degron sequences are cell context dependent and vary according to the 
IMiD, with small changes in chemical structure leading to altered substrate 
specificity. Thus, further understanding is required to inform such a rational degron-
based approach.  
 
3. Hijacking E3 ligases for specific target degradation using bifunctional 
molecules 
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 3.1.  Hijacking the von Hippel-Lindau E3 ligase 
An alternative approach to achieve targeted protein degradation with chemical 
compounds involves the use of larger bifunctional molecules consisting of distinct 
substrate binding and E3 ligase binding groups conjugated by a linker; as first 
demonstrated for the recruitment of the Skp1-Cullin-F box complex containing Hrt1 
(SCF) ubiquitin ligase complex to degrade methionine aminopeptidase-2 (MetAP-2) 
(Sakamoto et al., 2001). The conjugate molecule serves to assemble a ternary 
complex between the E3 ligase, target protein and probe molecule, allowing the E3 
ligase complex to ubiquitinate the non-natural substrate and promote proteasome-
dependent degradation (illustrated for the von Hippel-Lindau (VHL) E3 ligase in 
Figure 4A). Whereas binding of the low molecular weight IMiD molecules discussed 
above results in a subtle variation in the E3 ligase receptor binding surface, changing 
the affinity and specificity for protein-protein interactions with substrates, the 
bifunctional molecule approach creates a spatially distinct small molecule binding 
site for protein substrates proximal to, but separate from, the E3 ligase itself. For a 
productive ternary species to be formed, the bifunctional molecule must contain a 
selective ligand for the target protein of interest with a suitable position for 
attachment of a recognition group for the E3 ligase via a linker group, without 
substantial loss of target affinity. In addition, the proximity and orientation of the E3 
ligase and target protein in the ternary complex must be permissive for target protein 
ubiquitination. 
Recruitment of the VHL E3 ligase to induce degradation of targeted proteins is so far 
the most extensively explored approach to hijacking the ubiquitin proteasome 
system, following the first demonstration of proof-of-concept by PROteolysis 
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TArgeting Chimeras (PROTACs) from Deshaies, Crews and colleagues (Sakamoto 
et al., 2001; reviewed in Raina & Crews, 2010; Buckley & Crews, 2014; Toure & 
Crews, 2016; Lai & Crews, 2016). Initially, small peptide chains were used to mimic 
the protein-protein interaction between the VHL E3 ubiquitin ligase complex and the 
endogenous substrate, hypoxia inducible factor 1α (HIF1α). The minimal recognition 
domain amino acid sequence ALAPYIP (Hon et al., 2002) contains a key central 
proline motif, analogous to P564 in HIF1α that becomes hydroxylated in cells 
ultimately leading to ubiquitination and degradation of HIF1α under normoxic 
conditions (Epstein et al., 2001). 
The first cell permeable bifunctional molecules included PROTAC-4 (Figure 4B) that 
was designed to target the F36V mutation of FK506 binding protein (FKBP12) 
(Schneekloth et al., 2004). The VHL-interacting seven amino acid peptide sequence 
was appended to the ligand AP21998 that targets a mutant FKBP12. To confer cell 
permeability and a degree of stability to proteolysis, a poly-D-arginine tag was also 
introduced to PROTAC-4. Consequently, F36V mutant FKBP12 protein fused to a 
green fluorescent protein (GFP) tag expressed in HeLa cells was shown in a 
fluorescence assay to be degraded by treatment with PROTAC-4 at a concentration 
of 25 µM over 2.5 h. As further proof that the bifunctional molecules could be 
effective at inducing selective protein degradation in cells, PROTAC-5 (Figure 4B) 
was designed using the same seven amino acid-polyarginine peptide. In this 
instance, the peptide motif was conjugated to dihydrotestosterone (DHT) to target 
the androgen receptor (AR). Fluorescence analysis of GFP-labelled AR in HEK293 
cells showed protein degradation after 1 h exposure to PROTAC-5 at concentrations 
of 25 µM and above. Additionally, pre-treatment with the proteasome inhibitor 
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epoxomicin prevented degradation of the GFP-AR protein, as did treatment alone 
with either testosterone or the truncated peptide-polyarginine construct.  
The bifunctional molecule E2-penta (Figure 4B) was used to hijack the VHL VBC-
CUL2 complex to ubiquitinate and degrade estrogen receptor α (ERα) in a potential 
approach to anti-angiogenesis (Bargagna-Mohan et al., 2005). Endogenous 
17β estradiol (E2) promotes angiogenesis via ERα by direct endothelial cell 
proliferation, migration and up-regulation of basic fibroblast growth factor and 
vascular endothelial growth factor (VEGF) and their receptors. Introduction of the 
pre-hydroxylated proline motif, the key recognition factor in the degradation of 
HIF1α, allowed the chain to be shortened to a pentapeptide that showed improved 
potency over longer peptide analogues, presumably due to better cell permeability. 
Inhibition of VEGF-induced sprouting of human umbilical vein endothelial cells 
occurred following incubation with 2 µM concentrations of E2-penta over 24 hours. 
This was the first report of using PROTACs to perturb downstream biological 
function and provided proof of concept for using such chemical probes to degrade 
target proteins and study the biological consequences. 
The aryl hydrocarbon receptor (AHR) is present in the cytoplasm as part of a 
chaperone complex and has been implicated in tumour promotion and progression. 
Apigenin-Protac (Figure 4B), containing the hydroxylated pentapeptide VHL-
recognition domain, was found to bind significantly less strongly to AHR than the 
unconjugated AHR ligand apigenin (Apigenin-Protac IC50 = 4 µM, compared to 
Apigenin IC50 = 0.3 µM) (Puppala et al., 2008). Despite this ten-fold decrease in 
binding affinity, Apigenin-Protac was found to degrade AHR protein levels in 
neonatal primary human keratinocytes (NHK) at concentrations of 10 µM after 12 h 
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incubation, in addition to inhibiting expression of 2,3,7,8-tetrachlorodibenzo-p-dioxin-
induced cytochrome P450 1A1 (CYP1A1) protein, a biomarker of AHR function. 
Usefully, a negative control bifunctional molecule was also reported, whereby the 
hydroxyproline amino acid critical for VHL recognition was replace with alanine, and 
was shown to have no effect on AHR degradation.  
In a recent example, the hydroxylated pentapeptide VHL-recognition motif was used 
to target SMAD3, a key signalling protein in renal fibrosis, for degradation (Wang et 
al., 2016). In the absence of a suitable small molecule SMAD3 inhibitor, an in silico 
docking screen of a commercial library was performed. Of the hits thought possibly 
suitable as PROTAC components and confirmed by surface plasmon resonance 
(SPR) as SMAD3 ligands, a benzofuran ligand with moderate binding affinity (Kd = 
45 µM) and slow off-rate was selected for inclusion in the bifunctional conjugate 
Smad3-Protac (Figure 4B). The molecule was found to decrease basal SMAD3 
protein expression in both renal fibroblast (NRK-49F) and renal mesangial cells 
(HMC) at 200 µg/mL concentration, representing an approximate 100-fold reduction 
in potency compared to the activity observed in human renal carcinoma ACHN cell 
lysates, and illustrating the difficulty of routinely obtaining high cell permeability with 
large bifunctional molecules containing significant peptidic character.  
A two-headed approach to the design of PROTAC-type conjugates was explored in 
the context of estrogen receptor (ER) degradation (Cyrus et al., 2010). The two-
headed PROTAC (Figure 4B) was found to have a three-fold improved binding 
affinity for ER in comparison to two control PROTAC molecules each containing a 
single ER-targeting head group at either the N- or C-terminus of the VHL targeting 
pentapeptide. The linker length between ER ligand and VHL targeting peptide in the 
PROTAC was found to be important for activity (Cyrus et al., 2011). Although 
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observed to have poorer solubility than the monomeric counterparts, two-headed 
PROTAC had improved ability to induce ER degradation at 10 µM over 48 h 
incubation, with a greater than 5-fold enhancement of potency over monomeric 
counterparts. Importantly, to demonstrate mechanism of action, the control 
compound where the central hydroxyproline VHL recognition amino acid was 
replaced with norleucine did not cause ER degradation under the same conditions, 
nor did degradation occur with two-headed PROTAC in the presence of the 
proteasome-specific inhibitor epoxomicin.  
An exciting extension of the bifunctional conjugate approach whereby the conditional 
degradation of a protein target occurs only subsequent to an intracellular 
phosphorylation event has been developed (Hines et al., 2013). As an example, the 
tyrosine residue highlighted in TrkAPPFRS2α (Figure 4B) must first be phosphorylated 
by the kinase, tropomyosin receptor kinase A (TrkA), before degradation of the 
target, fibroblast growth factor receptor substrate 2 (FRS2α), is observed. In the 
presence of nerve growth factor (NGF), TrkA undergoes NGF-induced dimerization 
and trans-autophosphorylation. The fully active phosphorylated tyrosine kinase can 
in turn bind and phosphorylate a number of substrates, including FRS2α. TrkAPPFRS2α 
was designed to incorporate a ten amino acid recognition sequence around the 
tyrosine residue phosphorylated in TrkA, a seven amino acid recognition sequence 
to bind to VHL and a polyarginine sequence to improve cell permeability. In the 
presence of TrkAPPFRS2α, NGF-treated PC12 cells incorporated radiolabelled 32P 
phosphate into the TrkAPPFRS2α conjugate, a phenomenon not observed in the 
absence of NGF. Incubating PC12 cells in the presence of NGF for 7 h showed an 
increase in phosphorylation of FRS2α with no loss of protein levels. However, 
including 40 µM TrkAPPFRS2α gave a 50% reduction in FRS2α protein levels as well as 
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loss of downstream ERK1/2 phosphorylation, without any associated decrease in 
overall ERK1/2 protein levels. Pre-treatment of PC12 cells with epoxomicin was used 
to confirm dependence on the ubiquitin-proteasome pathway, and indeed caused 
accumulation of FRS2α and higher molecular weight FRS2α-ubiquitin conjugates in 
the presence of NGF and TrkAPPFRS2α. The requirement for TrkA phosphorylation of 
TrkAPPFRS2α to induce degradation was supported by use of a Phe/Tyr residue swap 
in a control bifunctional molecule, thus removing the site of potential 
phosphorylation, and giving no FRS2α degradation or reduction in ERK1/2 
phosphorylation in the presence of NGF.  
A further example of the conditional degradation strategy was described using 
ErbB2PPPI3K (Figure 4B) to deplete phosphatidylinositol-3-kinase (PI3K). ErbB3 
phosphorylation in a heterodimer complex between ErbB2 and ErbB3 epidermal 
growth factor (EGF) receptor tyrosine kinases at the cell membrane results in 
recruitment of PI3K through binding to phospho-ErbB3. The design of the 
phosphoPROTAC ErbB2PPPI3K therefore contained a 24 amino acid sequence taken 
from the PI3K binding segment of ErbB3. Both the highlighted tyrosine residues in 
Figure 4B are phosphorylated by ErbB2, leading to recruitment of PI3K for 
degradation. Accordingly, ErbB2PPPI3K induced depletion of PI3K expression in MCF-7 
cells at concentrations of 40 µM and above. Replacing the Tyr residues in ErbB2PPPI3K 
with Phe as before confirmed the requirement of tyrosine phosphorylation to occur 
before observing any reduction in PI3K protein levels. Additionally, a mouse study 
using 10 mg/kg i.p. dosing of ErbB2PPPI3K in OVCAR8 subcutaneous xenograft 
tumours demonstrated a 40% reduction in tumour weight relative to control. 
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While cellular and in vivo efficacy has been shown in peptide derived VHL affinity 
groups as discussed above, the use of a non-peptide, selective small molecule VHL 
recognition motif could offer a number of advantages in regard to improved potency, 
metabolic stability and permeability. The rational design of small molecule VHL 
ligands such as cmpd 15 (Figure 5A) and determination of its crystal structure bound 
to VHL (Buckley et al., 2012) has led to the development of submicromolar VHL 
ligands with reduced peptide character (Galdeano et al., 2014). Incorporation of a t-
butyl group in the VHL binding component, as in Protac_ERRα (Figure 5A), has 
been found to give high affinity for VHL (Bondeson et al., 2015). Protac_ERRα gave 
50% degradation (DC50) of ERRα in MCF-7 cells at 100 nM, whereas the epimeric 
proline alcohol, used as a negative control as it no longer binds to VHL, gave 
approximately 20% degradation at the same concentration. In addition, 
Protac_ERRα showed depletion of ERRα in vivo when dosed at 100 mg/kg i.p., 
three times per day, to mice bearing MDA-MB-231 xenograft tumours. Similarly, 
Protac_RIPK2 (Figure 5A) was shown to be particularly potent in inducing 
degradation of RIPK2, with a DC50 of 1.4 nM in human THP-1 monocytes and 
complete depletion at 10 nM. Of note was a biphasic response at high 
concentrations of Protac_RIPK2, where protein levels of RIPK2 recovered to basal 
levels, an effect attributed to an inability to form the proposed ternary complex in the 
presence of excess Protac_RIPK2 concentrations, which increases binary complex 
formation and thus stops degradation. The epimeric proline alcohol of Protac_RIPK2 
made as a negative control did not show any degradation at concentrations up to 10 
µM. Both active Protac_RIPK2 and the inactive epimeric alcohol were used to 
provide evidence to support the formation of a ternary complex through 
chemoproteomic pulldown and immunoprecipitation experiments. Moreover, 
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Protac_RIPK2 was found to act catalytically in vitro, inducing super-stoichiometric 
ubiquitination of RIPK2. For both Protac_ERRα and Protac_RIPK2, a dependence 
on proteosomal degradation in cells was confirmed by pretreatment with the 
proteasome inhibitor epoxomicin, resulting in blockade of the degradation of ERRα 
and RIPK2. The specificities of Protac_ERRα and Protac_RIPK2 towards 
degradation of their intended target proteins were assessed by cellular expression 
proteomics in cancer cells, monitoring approximately 7600 proteins. For 
Protac_ERRα only degradation of ERRα and (after prolonged exposure) break point 
cluster region protein (BCR) was observed, while Protac_RIPK2 showed a similar 
specificity with RIPK2 and the kinase MAPKAPK3 as the only proteins degraded. 
The treatment of chronic myelogenous leukemia (CML) by inhibition of the oncogenic 
protein kinase BCR-ABL using small molecule drugs such as imatinib, dasatinib or 
bosutinib has been highly effective. There is, however, a need for lifelong treatment 
with the drug, speculated to be due to the ability of BCR-ABL to act as a scaffolding 
protein in a compensatory pathway that produces leukemic stem cells in spite of 
kinase inhibition. Degradation of BCR-ABL therefore presents an alternative 
approach to modulation of this important target (Lai et al., 2016). Of the VHL binding 
conjugates synthesised with varying linker group lengths, DAS-6-2-2-6-VHL (Figure 
5A) showed degradation of the wild type protein c-ABL at 1 µM in K562 human CML 
cells over 24 h. However, no associated degradation of the oncogenic BCR-ABL 
fusion protein was observed, despite potent binding of dasatinib to both proteins, and 
in contrast to the effects of related conjugates designed to recruit the cereblon E3 
ligase complex, discussed in detail in Section 4. Thus, a clear need to optimise not 
only the target binding motif and linker length in the bifunctional molecules, but also 
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the choice of E3 ligase for recruitment in a given degradation target context, has 
been demonstrated. 
The bifunctional molecule ARV-771 (Figure 5A) has been found to induce potent 
degradation of the bromodomain and extra terminal domain (BET) family of proteins, 
potentially of great interest in the treatment of prostate cancer, and castration-
resistant prostate cancer (CRPC) in particular (Raina et al., 2016). ARV-771 was 
constructed by conjugating JQ-1, a small molecule BET inhibitor, to a 
hydroxyproline-based VHL binding domain via an optimised linker group. 
Degradation of the BET family of proteins BRD2, 3 and 4 by ARV-771 was observed 
in 22Rv1, VCaP and LnCaP95 human prostate cancer cell lines at concentrations of 
5-10 nM. Loss of expression of c-MYC, a downstream effector of BET, was also 
observed at both the protein and mRNA levels at <10 nM concentrations for ARV-
771. An inactive control diastereoisomer ARV-766, containing the epimeric proline 
alcohol unable to bind VHL, was found to have comparable binding affinity for the 
BET proteins to that seen for ARV-771 and JQ-1. ARV-766 showed a negligible 
effect on c-MYC mRNA levels at 1 µM despite being a potent BET inhibitor in its own 
right, suggesting poor permeability. Given that the active conjugate ARV-771 may be 
expected to have comparable cell permeability, the low nanomolar cellular activity 
observed for ARV-771 has been hypothesised to be due to the potential catalytic 
action of the bifunctional species. Additionally, ARV-771 was shown to induce BRD4 
and c-MYC degradation in 22Rv1 tumour xenografts in mice, and more importantly 
led to tumour regression in the 22Rv1 model following daily subcutaneous dosing of 
30 mg/kg. 
Variation of the linker length between JQ-1 and the VHL binding motif has led to the 
discovery of linker-dependent selectivity within the BET family of proteins (Zengerle 
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et al., 2015). MZ1 (Figure 5A) and JQ-1 were shown to have comparable binding 
affinities for the BET family of proteins, however, MZ1 was found to preferentially 
degrade BRD4 over BRD2 and BRD3  at a concentration of 1 µM in HeLa cells over 
24 h. In the U2OS cell line, MZ1 demonstrated dose- and time-dependent selective 
degradation of BRD4 over BRD2 and BRD3. Furthermore, MZ1 was shown to have 
no effect on endogenous levels of VHL or HIF1α, an important factor in the potential 
use of such bifunctional molecules as drug therapies.  
 
3.2. Bifunctional molecules hijacking the MDM2, cIAP and CRBN E3 ligases. 
E3 ligases other than VHL have been successfully hijacked using bifunctional 
molecules. The first non-peptidic E3 ligase targeting group was used to direct 
MDM2, whose natural substrate is the tumour suppressor TP53, to degrade the 
androgen receptor (AR) (Figure 6A) (Schneekloth et al., 2008). A selective androgen 
receptor modulator (SARM) with nanomolar affinity for AR was conjugated to the 
MDM2-TP53 interaction inhibitor nutlin to generate the SARM-nutlin PROTAC which 
decreased AR expression in HeLa cells in a proteasome-dependent manner at 10 
µM concentration (Figure 6B, C). However, interpretation of the cellular activity of the 
SARM-nutlin PROTAC is complicated as AR is known to be a direct substrate of 
MDM2 (Lin et al., 2002) and nutlin itself induces ubiquitination and degradation of AR 
in cancer cells (Logan et al., 2007), raising the possibility of a direct modulatory 
effect of the SARM-nutlin bifunctional molecule on AR degradation independent of 
ternary complex formation (Itoh et al., 2010b; Tinworth et al., 2016). 
While the cellular potency for SARM-nutlin PROTAC was similar to that seen for 
VHL-targeting peptidic PROTACs, subsequent iterations using small molecule E3 
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ligase binding groups have achieved breakthroughs in cell activity to the nanomolar 
range, notably for non-peptidic molecules hijacking VHL (Figure 5A, B) and CRBN 
(Figure 6B, C). A suite of bifunctional molecules, termed specific and non-genetic 
IAPs-dependent protein erasers (SNIPERs) was developed by Hashimoto and 
colleagues to redirect the activity of the E3 ligase cIAP1 that degrades caspase 
proteins and is over-expressed in many cancer cells (Figure 6A). The conjugates 
make use of derivatives of bestatin methyl ester, a cell permeable small molecule 
which binds to cIAP1 to promote autoubiquitination and degradation (Sekine et al., 
2008). Proof-of-concept was achieved with SNIPER cmpd 4 (Figure 6B) that linked a 
bestatin ester moiety to all-trans retinoic acid (ATRA) to capture the cellular retinoic 
acid binding proteins (CRABP-I and -II) (Itoh et al., 2010). Proteasome-dependent 
degradation of CRABP-I/II was observed between 1 – 10 µM in cells. Interestingly, 
varying the linker length in SNIPER cmpd 4 changed the relative efficiency of 
degradation of CRABP-I and -II, with CRABP-I better depleted by a conjugate with 
longer linker. Reduced expression of CRABP-II in IMR-32 human neuroblastoma 
cells by SNIPER cmpd 4 gave a dose-dependent reduction in cell motility. 
To avoid the concomitant autoubiquitination and degradation of cIAP promoted by 
bestatin ester derivatives, the amide-linked SNIPER cmpd 6 was developed to retain 
cIAP binding but abolish autodegradation (Itoh et al., 2011a). SNIPER cmpd 6 
promoted depletion of CRABP-II from 1 µM in cells with no effect on cIAP levels or 
apparent inhibition of cIAP endogenous function. A comparison of the effects of 
SNIPER cmpd 4 and cmpd 6 in IMR-32 neuroblastoma cells showed that combined 
CRABP-II and cIAP degradation was advantageous for inhibition of cell growth and 
induction of apoptosis. Amide-linked SNIPERs have also been described for targeted 
depletion of nuclear receptors, namely retinoic acid receptor (RAR; cmpd 9, Figure 
22 
 
6B), estrogen receptor (ER; cmpd 11, Figure 6B) and androgen receptor (AR; cmpd 
13, Figure 6B), albeit with reduced cell potency (Figure 6C) (Itoh et al., 2011b). 
A bifunctional molecule SNIPER(TACC3) was designed to induce degradation of the 
mitotic spindle regulatory protein transforming acidic coiled-coil-3 (TACC3) (Figure 
6B) (Ohoka et al., 2014). While ubiquitination- and proteasome-dependent depletion 
of TACC3 was observed in cells treated with SNIPER(TACC3), this was 
unexpectedly found not to be due to recruitment of the cIAP E3 ligase as anticipated. 
Instead, mechanistic studies showed the degradation was mediated by the ubiquitin 
ligase, anaphase-promoting complex/cyclosome in complex with CDH1 (APC/CCDH1). 
APC/CCDH1 is the E3 ligase responsible for TACC3 degradation in unperturbed cells, 
but a physical interaction between the SNIPER(TACC3) molecule and APC/CCDH1 
was demonstrated by thermal stability assay, suggesting that both SNIPER(TACC3)-
dependent and independent mechanisms may contribute to TACC3 degradation. 
The cause of this switch in E3 ligase recruitment by the bestatin-linked bifunctional 
molecule remains unclear. These findings indicate that a consistent mechanism of 
action is not guaranteed for newly designed bifunctional molecules, and that proof of 
mechanism of action is required to accompany their use as chemical probes. 
High cellular potency for targeted protein degradation has been achieved with 
bifunctional molecules that recruit CUL4CRBN (Figure 6A). ARV-825 PROTAC (Figure 
6B), consisting of a high affinity triazolo-diazepine related to the potent BRD4 
inhibitor JQ01 conjugated to a pomalidomide derivative, was designed to promote 
CRBN-dependent degradation of the BRD4, a member of the BET family of 
epigenetic reader proteins (Lu et al., 2015). The conjugate retained high affinity for 
BRD4 (Kd = 28 nM for bromodomain 1 of BRD4) and showed complete degradation 
of BRD4 in cells at 100 nM concentration (Figure 6C), suggesting that the 
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bifunctional molecule is acting catalytically with respect to recruiting BRD4. Of note, 
the affinity of pomalidomide for CRBN is only ca. 3 µM, again indicating that each 
bifunctional molecule participates in more than one recruitment cycle, and that 
transient linking of the target protein and E3 ligase is sufficient for efficient 
ubiquitination. A bell-shaped concentration response curve was observed for 
degradation of BRD4 in cells, consistent with the formation of a trimeric BRD4/ARV-
825 PROTAC/CRBN complex as the active species promoting ubiquitination. The 
observed sustained protein degradation was in contrast to the effects of 
unconjugated BRD4 ligands which lead to hyper-accumulation of BRD4 on 
prolonged exposure. As a result, increased downstream effects on suppression of c-
MYC protein, inhibition of B-cell proliferation and induction of apoptosis were seen 
for the conjugate compared to unconjugated BRD4 ligands. 
In a parallel approach, the conjugation of the BRD4 inhibitor JQ01 to a 
pomalidomide/thalidomide hybrid gave the bifunctional molecule dBET1 (Figure 6B) 
that retained the selectivity of JQ01 for BRD4 binding within the BET family (Winter 
et al., 2015). Taking advantage of the crystal structures available for both BRD4 and 
CRBN with ligands bound, the linker length for dBET1 was designed based on in 
silico modelling of the ternary complex. Extensive depletion (>85%) of BRD4 by 
dBET1 was seen at 100 - 250 nM in human cells for up to 18 h (Figure 6C). Some 
recovery of protein levels were seen on longer exposure, suggestive of chemical 
instability of the bifunctional molecule. Proteomic assessment of the effects of 
dBET1 and the unconjugated BRD4 inhibitor JQ01 showed highly similar, selective 
effects of both molecules. Out of 7429 proteins monitored, the bifunctional molecule 
dBET1 elicited depletion of MYC and PIM1 as expected based on the downstream 
effects of depletion of BRD4, and only three other proteins (BRD2, BRD3, BRD4), 
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consistent with the specificity of the JQ01 ligand for the BET family. However, 
enhanced apoptotic effects were seen for dBET1 in cancer cell lines and primary 
human acute myeloid leukaemia cells. The effects of targeted degradation of BRD4 
were investigated in vivo following intraperitoneal dosing of dBET1 to mice bearing 
xenograft human MV4-11 leukaemia cells. Inhibition of tumour growth relative to 
untreated controls was observed, with pharmacodynamic evidence of BRD4 
depletion in treated tumours seen. A head-to-head comparison of equimolar 
amounts of dBET1 and JQ01 dosed in a model of disseminated leukaemia showed a 
ca. three-fold increase in anti-tumour activity for the bifunctional molecule over the 
simple BRD4 ligand. 
Conjugation to CRBN-recruiting groups has also been demonstrated for the FKBP12 
ligand steel factor (SLF), giving the potent promoter of FKBP12 degradation, dFKBP-
1 (Figure 6B) (Winter et al., 2016), as well as to the BCR-ABL receptor tyrosine 
kinase inhibitors bosutinib and dasatinib, to give BOS-6-2-2-6-CRBN and DAS-6-2-2-
6-CRBN, respectively (Figure 6B) (Lai et al., 2016). In the latter study, Crews and 
colleagues adopted a modular approach to vary the affinity group (kinase inhibitor), 
linker structure and E3 ligase recruiting group of the PROTAC molecules. This 
allowed a direct comparison between recruitment of VHL and CRBN E3 ligases for 
the same targets. The crystal structures of ligand-bound c-ABL were used to select 
the attachment points for the linkers and the derived bifunctional molecules 
maintained nanomolar affinity for BCR-ABL despite a general fall in potency. 
Intriguingly, none of the conjugates made that targeted VHL led to BCR-ABL 
degradation in cells (see Section 3). This was not due to lack of BCR-ABL binding, 
and was speculatively attributed to an unproductive orientation of the VHL E3 ligase 
in the trimeric complexes. In contrast, the conjugates recruiting CRBN (e.g. BOS-6-
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2-2-6-CRBN and DAS-6-2-2-6-CRBN) elicited potent degradation of BCR-ABL in 
cells, showing that the oncogenic tyrosine kinase has varying levels of susceptibility 
to modification by different hijacked E3 ligases. As the efficiency and selectivity of 
target degradation was also found to depend on the kinase inhibitor moiety, the 
authors suggest that a modular approach to an array of bifunctional molecule 
designs, to optimise empirically the best combination of target and E3 ligase binding 
functionalities, may be advantageous when seeking new probes for targeted protein 
degradation. Such studies require rapid syntheses of the components of the 
bifunctional molecules, such as that recently demonstrated for amine-substituted 
phthalimide derivatives (Lohbeck & Miller, 2016). 
A recent publication shows how high molecular weight bifunctional molecules can be 
self-assembled in situ in cells from smaller components using bio-orthogonal ‘click’ 
chemistry to link separate precursors containing the CRBN-binding and protein 
targeting functionalities (Lebraud et al., 2016). These click-formed proteolysis 
targeting chimeras (CLIPTACs) recruiting CRBN were prepared by conjugation of 
thalidomide to JQ1 (JQ1-CLIPTAC) or to a covalent ERK1/2 inhibitor (ERK1/2-
CLIPTAC) to achieve depletion of BRD4 or extracellular signal-regulated kinases 
(ERK) 1 and 2, respectively. A potential advantage for achieving cell penetration with 
smaller components was demonstrated by the observation that pre-formed 
CLIPTACs gave no target degradation; while combination of the smaller click-
enabled thalidomide moiety (10 µM) with click-enabled JQ1 (3 µM) gave complete 
BRD4 depletion after 18 h. 
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3.3. Targeted protein degradation through recruitment of HSP70 molecular 
chaperones or direct binding to the 20S proteasome. 
The bifunctional molecules described above effect protein degradation by direct 
binding to E3 ligase complexes. Protein ubiquitination and degradation can also be 
achieved through hijacking the unfolded protein response using very lipophilic small 
molecule tags to recruit molecular chaperones, such as HSP70 family members that 
recognise the exposed hydrophobic cores of unfolded proteins (Figure 7Ai). HSP70 
and co-chaperone binding directs the tagged protein for E3 ligase-mediated 
ubiquitination and degradation as though it were an unfolded client. First 
demonstrated for Halotag proteins (Nekelsa et al., 2011) using an adamantly 
hydrophobic tag, this approach was extended to bifunctional adamantyl derivatives 
including the selective androgen receptor degrader SARD279 (Figure 7B) 
(Gustafson et al., 2015). Conjugation of the high affinity AR agonist RU59063 to the 
adamantyl group reduced the binding affinity for AR by 37-fold, but led to 
degradation of AR in LNCaP human prostate cancer cells at low micromolar 
concentrations, while no AR degradation was seen upon treatment with 
unconjugated RU59063. Selective degradation of AR over the glucocorticoid 
receptor (GR) was induced by SARD279, consistent with the selectivity of the 
RU59063 affinity group for AR over GR. Increasing the cellular expression of HSP70 
isoforms using the HSP90 inhibitor geldanamycin enhanced the SARD279-
dependent AR degradation, suggesting a role for HSP70 in mediating degradation of 
the AR-SARD279 complex. SARD279 showed more potent inhibition of AR-
dependent gene expression (IC50=156 nM) than for AR degradation, indicating a 
dual mode of activity through competitive inhibition of AR transactivation as well as 
AR depletion. Importantly, in contrast to competitive AR antagonists, eliminating AR 
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protein with SARD279 was found to be anti-proliferative in AR-dependent prostate 
cancer cell lines and also in castrate resistant prostate cell lines, whether resistance 
to anti-androgens resulted from increased androgen levels or from the F876L AR 
mutation that converts antagonists to agonists (Gustafson et al., 2015). 
A distinct approach to targeted protein degradation was achieved using ligands 
linked to arginine triply-protected with the bulky, lipophilic tert-butyloxycarbonyl (Boc) 
group (Long et al., 2012). Thus, the Boc3-protected arginine (B3A) conjugate of the 
covalent glutathione S-transferase (GST) inhibitor ethacrynic acid (EA-B3A, Figure 
7B) induced degradation of GST-fusion proteins in lysates from HeLa cancer cells, 
and of endogenous GST-π as well as ectopically expressed GST-fusion proteins in 
Cos-1 or HeLa cells. Covalent attachment of the affinity group to the target protein 
appeared to enhance the degradation potency of the bifunctional molecules. The 
conjugate TMP-B3A (Figure 7B) based on trimethoprim, a reversible, non-covalent 
inhibitor of bacterial dihydrofolate reductase (eDHFR), was tested head-to-head with 
EA-B3A for the ability to promote degradation of an ectopically expressed eDHFR-
HA-GST-α1 fusion protein in HeLa cells. While 80 µM EA-B3A gave complete 
depletion of the fusion protein in under 2 h, only 25% removal of protein was 
achieved by 80 µM TMP-B3A after 5 h. 
In contrast with other targeted degradation approaches, the mechanism of B3A-
promoted degradation was found not to require ubiquitination of the target protein, 
nor the involvement of the 26S proteasome (Long et al., 2012; Shi et al., 2016). 
Neither did binding of B3A conjugates intrinsically destabilise the target proteins and 
induce unfolding. Instead, a direct non-covalent interaction of the B3A group with the 
20S proteasome was uncovered, and purified 20S proteasome was found to be 
sufficient for target protein degradation in cell free systems. Thus, this represents the 
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first example of using a bifunctional small molecule for direct targeting of a protein to 
the 20S proteasome for degradation (Figure 7Aii) and is an exciting addition to the 
growing repertoire of pharmacological techniques to control protein degradation. 
The two approaches outlined above offer complimentary alternatives to the hijacking 
of specific E3 ligases to achieve targeted protein degradation. The hydrophobic and 
B3A tags do not have the same potential to alter endogenous E3 ligase substrate 
specificity as may be seen with VHL- or CRBN-directing tags, but there are other 
potentially interfering biological outputs from the functional groups in the conjugate 
molecules that may complicate interpretation of cellular experiments. HaloTag 
protein modification with adamantyl-derived groups can induce a transient unfolded 
protein response (Raina et al., 2014). While it is not demonstrated that this applies 
for the reversible, bifunctional molecules, the activation of HSP70 isoforms could 
complicate the phenotype seen on targeted degradation. On the other hand, the 
simple B3A-containing molecule Cbz-B3A (Figure 7B) which lacks a specific affinity 
group has been shown to block eIF4E-binding protein 1 (4EBP1)-dependent 
translation through an as yet uncharacterised interaction with ubiquilins (Coffey et 
al., 2016). These inevitable caveats of reagent selectivity notwithstanding, 
pharmacological degradation of putative targets by more than one of the 
complementary approaches available would help to rule out off-target effects. 
 
3.4. Experimental approaches to characterising bifunctional modulators of 
E3 ligase activity 
The discovery and validation of new bifunctional molecules to hijack E3 ligases 
requires characterisation of their mode of action, especially if they are to be used 
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effectively as tools to explore the biological consequences of specific protein 
depletion. This mirrors the validation of classical small molecule chemical probes 
(Workman & Collins, 2010). The common experimental approaches applied to 
characterise PROTACs, SNIPERs and other bifunctional molecules are summarised 
in Table 1. These typically provide evidence for; engagement of the target protein(s) 
and E3 ligase, trimeric complex formation, ubiquitin- and proteasome-dependent 
degradation of the target, specificity for the target, and differentiation of the 
bifunctional compound from the component binding groups. In most cases these 
experiments are supported by the parallel discovery and profiling of negative control 
compounds, typically bifunctional molecules where one of the binding groups has 
been rendered ineffective, as well as the use of competition experiments between 
the bifunctional probe and the small molecule component binding groups. Details of 
these approaches are presented in many of the publications surveyed in Section 3.    
Table 1: Common experimental approaches to characterising bifunctional 
modulators of E3 ligase activity for their suitability as chemical tools 
Characterisation Experimental approaches 
• Evidence of target degradation • Cell-based assessment of target protein 
expression 
• Dose-dependent depletion of target protein and 
quantification of potency (DC50, DC90 or similar) 
• Evidence of binding to target protein  • Biochemical (cell-free) assay of binding/inhibition 
by the bifunctional molecule 
• Cell-based assay for inhibition of function of the 
target protein by the bifunctional molecule 
• Reduction of target degradation in cells by 
competition with the unconjugated affinity group 
and/or an alternative small molecule targeting the 
same binding site 
• Evidence for binding and recruitment of  
an E3 ligase 
• Reduction of target degradation in cells by 
competition with the unconjugated recruitment 
motif for the E3 ligase  (e.g. pomalidomide for 
CRBN) 
• Target degradation abolished in ligase-deficient 
cell lines 
• Evidence for ubiquitin-dependent 
degradation 
• Assay for ubiquitination of the target protein 
following immunoprecipitation from cells treated 
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with the bifunctional molecule and a proteasome 
inhibitor (e.g. MG132) 
• Evidence for 26S proteasome-dependent 
degradation 
• Inhibition of probe-induced target degradation in 
the presence of a proteasome inhibitor (eg 
MG132, carfilzomib, epoxomicin) 
• Evidence of a trimeric complex formation 
(E3 ligase – bifunctional molecule – target 
protein) mediating the observed effects 
• Bell-shaped concentration-response for target 
protein degradation in cells (may only be seen for 
potent probes) or in a cell-free proximity assay 
(e.g. AlphaScreen) 
• Confirmation that target degradation induced by 
the bifunctional molecule is not induced by 
derivatives of the unconjugated affinity group or 
ligase recruitment group alone, or a mixture of the 
two. 
• Recovery of the target protein following 
immunoprecipitation of the E3 ligase in cells 
treated with the bifunctional molecule  
• Cell-free proximity assay using labelled ligase and 
target protein 
• Evidence of specificity for target 
degradation 
• Biochemical (cell-free) profiling of bifunctional 
molecule for binding/inhibition based on activities 
of the affinity group 
• Cell-based assay for degradation of 
known/potential off-targets based on biochemical 
profiling of the bifunctional molecule or its 
unconjugated affinity group,  
• Cell-based assay for effects on the degradation of 
known substrates of the E3 ligase hijacked 
• Differentiation of degradation promoted by the 
bifunctional molecule compared to negative 
control compounds where either the target affinity 
or ligase recruitment groups are replaced by 
structurally related, non-binding analogues (e.g. 
epimeric derivatives) 
• Cellular expression proteomic profiling to 
determine effects on degradation. 
 
4. Conclusions and future perspectives 
Two major recent breakthroughs have been achieved in the field of targeted protein 
degradation promoted by small molecules. One is the increased cell potency now 
routinely achievable using non-peptidic functionality in bifunctional molecules that 
engage E3 ligases to promote highly specific protein depletion (Deshaies, 2015). 
This has enabled multiple proof-of-concept demonstrations of activity in animals with 
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compounds promoting degradation of BET proteins or estrogen receptor related 
receptor-α (ERRα) (Winter et al., 2015; Bondeson et al., 2015; Raina et al., 2016). 
Importantly, two studies targeting BET protein degradation using bifunctional 
molecules that contain a BRD4 binding group showed anti-tumour activity in animal 
models, concomitant with the targeted protein degradation in vivo (Winter et al., 
2015; Raina et al., 2016). Optimising the physicochemical properties of high 
molecular weight bifunctional molecules to render them routinely suitable for human 
administration remains difficult (Whitty & Zhou, 2015), but these promising 
demonstrations of in vivo efficacy give impetus to solving this challenge. 
The second breakthrough, that already addresses achieving drug-like 
physicochemical properties with small molecules that redirect E3 ligase activity, 
comes from understanding and exploiting the IMiD class of small molecule 
modulators of cereblon substrate specificity. Here, the challenge is to learn how to 
predict and control the selectivity for neo-substrate degradation, and to discern what 
limitations may exist to specificity. It is very encouraging that effective drug 
molecules are already in clinical use from this approach, and this indicates that the 
pleiotropic effects of multiple target protein degradation can be successfully used for 
therapeutic benefit. 
The two chemical approaches to targeted protein degradation through modulation of 
the ubiquitin–proteasome pathway described in this article are highly 
complementary, both in terms of their current use and future prospects. There are 
common considerations, for example the possible consequences of competition with 
endogenous substrates of the particular E3 ligase hijacked, and the need to carefully 
validate the mechanism of action of the chemical probes. With bifunctional 
molecules, the biological effect of proteasome-mediated depletion of the target 
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protein needs to be differentiated from any direct effect of the affinity group on the 
target protein, especially when this is derived from a potent inhibitor or modulator in 
its own right. However, it is already clear that target depletion can have a more 
sustained activity than direct target inhibition, and can overcome intrinsic feedback 
activation or overexpression of the target (Lu et al, 2015). Exploiting the CRL4CRBN 
mediated degradation of target proteins with small molecules that modulate the 
receptor surface will require understanding of the target degron sequence, biological 
context and the development of chemical libraries that bind the tri-tryptophan cage in 
CRBN. Binding of substrates to “hotspot” interaction sites on CRBN and the ability to 
effect degradation selects for small molecules with low molecular weight and cell 
permeability which is a distinct advantage for developing drug like molecules. On the 
other hand there is limited further scope for further chemistry optimisation without 
perturbing the substrate specificity. For the bifunctional targeting approach, 
understanding the class of E3 ligase recruited, the optimal type of linker and how to 
assemble these is important, as well as the availability of specific binders for target 
proteins in the first place. Both complementary approaches therefore have 
advantages and disadvantages, but both will have an increasing role to play in the 
discovery of chemical probes for interrogating biological systems and the 
development of novel therapeutics through targeted protein degradation. 
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Figure 1 
 
 
Figure 1. Components of the CULLIN-RING ligase 4 (CRL4) 
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Figure 2 
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Figure 2. A Timeline (block arrows) of the development of immunomodulatory 
derivatives (IMiDs), the discovery of cereblon (CRBN) and its substrates. A timeline 
(circles) of key steps in the development of bifunctional molecules hijacking E3 
ligases described in this review is shown in parallel.. B Structures of published 
IMiDs.  
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Figure 3 
 
 
Figure 3. A The role of CUL4CRBN in mediating protein homeostasis of endogenous 
substrates (Meis2, and glutamine synthetase); the conserved tritryptophan pocket 
that binds IMiDs is highlighted. B Known protein substrates of consequence (for 
example, Aiolos, Ikaros, CK1α and GSPT1) whose rate of degradation is altered in 
response to the binding of thalidomide to the tritryptophan pocket of CUL4CRBN; as 
yet undiscovered substrates are denoted by X and Y. 
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Figure 4: Selected bifunctional molecules hijacking the Von-Hippel Lindau 
(VHL) E3 ligase using peptide motifs to target VHL. A Cartoon showing the 
complexes involved in VHL-dependent ubiquitination (ELBC, elongin B – elongin C 
heterodimer; CUL2, Cullin2; E2, E2 ubiquitin ligase; Ub, ubiquitin). B Structures of 
bifunctional molecules showing the affinity groups targeting proteins for degradation 
(red), linker motifs (black) and peptide motifs targeting the VHL E3 ligase (blue). Y 
denotes sites of intracellular phosphorylation. POH = hydroxyproline. C Proteins 
targeted for degradation by selected bifunctional molecules and the concentrations 
used in cellular assays where maximal target depletion was observed (AHR, aryl 
hydrocarbon receptor; AR, androgen receptor; ER, estrogen receptor; FKBP12, 
FK506 binding protein 12;  FRS2a, fibroblast growth factor receptor substrate 2; 
PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; SMAD3, SMAD family 
member 3).  
  
49 
 
Figure 5 
 
 
Figure 5: Selected bifunctional molecules hijacking the Von-Hippel Lindau 
(VHL) E3 ligase using small-molecule VHL inhibitors. A Structures of bifunctional 
molecules hijacking the Von-Hippel Lindau (VHL) E3 ligase, showing the affinity 
groups targeting proteins for degradation (red), linker motifs (black) and VHL E3 
ligase targeting motif (blue).B Proteins targeted for degradation by selected 
bifunctional molecules and the concentrations used in cellular assays where maximal 
target depletion was observed (BET bromodomain and extra-terminal family of 
proteins; BRD4 bromodomain-containing protein 4, member of the BET family; c-
ABL Abelson tyrosine kinase; RIPK receptor-interacting serine/threonine-protein 
kinase 1;  ERRα estrogen-related receptor alpha).  
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Figure 6: Selected bifunctional molecules hijacking the MDM2, cIAP1 and 
CRBN E3 ligases. A Cartoon showing the complexes involved in MDM2-, cIAP- and 
CRBN-dependent ubiquitination (cIAP, cellular inhibitor of apoptosis protein; CRBN, 
cereblon; CUL4, cullin4; DDB1, DNA damage binding protein 1; E2, E2 ubiquitin 
ligase; MDM2, mouse double minute 2 homolog; Ub, ubiquitin). B Structures of 
bifunctional molecules showing the affinity groups targeting proteins for degradation 
(red), linker motifs (black) and small molecule motifs that recruit the E3 ligases 
(blue). C Proteins targeted for degradation by selected bifunctional molecules, the 
E3 ligases recruited and the concentrations used in cellular assays where maximal 
target depletion  was observed (APC/CCDH1, anaphase-promoting 
complex/cyclosome in complex with CDH1; AR, androgen receptor; BCR-ABL, 
breakpoint cluster region – Abelson kinase fusion; BRD4, bromodomain 4;  c-ABL, 
Abelson murine leukemia viral oncogene cellular homolog; CRBP, cellular retinoic 
acid binding protein; ER, estrogen receptor; FKBP12, FK506 binding protein 12; 
RAR, retinoic acid receptor; TACC3, transforming acidic coiled-coil-3).  
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Figure 7 
 
Figure 7: Selected bifunctional molecules directing target degradation through 
binding of HSP70 or the 20S proteasome. A Cartoons showing the complexes 
involved in (i) HSP70-dependent protein degradation mediated by a hydrophobic 
adamantyl tag (HSP70, heat shock protein 70; Ub, ubiquitin) and (ii) direct 
recruitment of the 20S proteasome by Boc3Arg tags. B Structures of bifunctional 
molecules that direct target protein degradation through binding of HSP70 
(SARD279) or the 20S proteasome (EA-B3A, TMP-B3A) showing the affinity groups 
targeting proteins for degradation (red), linker motifs (black) and small molecule 
motifs targeting degradation machinery (blue). C Mode of action and proteins 
targeted for degradation, and the concentrations used in cellular assays where 
maximal target depletion was observed (AR, androgen receptor; eDHFR, E. coli. 
dihydrofolate reductase; GST-a1, glutathione S-transferase a1).  
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